Clarify Greaney et al. functional descriptions

[miseminger]

In S_convalescent_plasma_escape.txt.

# Highly ranked escape variant in most of the early and late convalescent sera in a study of 11 post-infection subjects.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
F456A

# Highly ranked escape variant in most of the early and late convalescent sera in a study of 11 post-infection subjects.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
F456T

# In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# E484P shows a resistant profile, but was mostly reduce or eliminated by  
# later time points (i.e. generally less resistant to immune cell somatic mutation evolution than E484Q of E484K), see Figure 5a,b.
# Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104.
# Subject B 26 days post-infection showed ~10 fold reduction in neutralization, but little immune escape at day 113.
# Subject G 18 days post-infection showed ~7 fold reduction in neutralization, but no immune escape at day 94.
# Notably, Subject G had no E484K/Q effect at either the early or late timepoints.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
E484P

# In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# E484Q shows a notably resistant profile, comparable to or even more resistant than E484K at 
# later time points (i.e. more resistant to immune cell somatic mutation evolution), see Figure 5a,b.
# Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104.
# Subject B 26 days post-infection showed ~10 fold reduction in neutralization, reducing to ~4x at day 113.
# Notably, Subject B also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 32, 
# and no E484K immune escape at day 104.
# Subject I 26 days post-infection showed ~10 fold reduction in neutralization, with no reduction in escape at day 102.
# Notably, Subject I also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 26, 
# and no E484K immune escape at day 102.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
E484Q

# In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# S484P shows a slightly resistant profile across both timepoints (i.e. resistant to immune cell somatic mutation evolution)
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
S494P

# In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# the early serum timepoint shows significant resistance (~10x or more), but both abate by the late timepoint (~3m) 
# presumably through immune cell somatic mutation evolution.
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
G446V

# In 1 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD, 
# this mutation shows significant resistence (~10x) at day 26, but waning resistence at day 102 (presumably due to immune cell somatic mutation evolution).
# Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003 [Journal publication]
G485R